<code id='3E8AF7A8A4'></code><style id='3E8AF7A8A4'></style>
      • <acronym id='3E8AF7A8A4'></acronym>
      <center id='3E8AF7A8A4'><center id='3E8AF7A8A4'><tfoot id='3E8AF7A8A4'></tfoot></center><abbr id='3E8AF7A8A4'><dir id='3E8AF7A8A4'><tfoot id='3E8AF7A8A4'></tfoot><noframes id='3E8AF7A8A4'>
      • <optgroup id='3E8AF7A8A4'><strike id='3E8AF7A8A4'><sup id='3E8AF7A8A4'></sup></strike><code id='3E8AF7A8A4'></code></optgroup>
        5. <b id='3E8AF7A8A4'><label id='3E8AF7A8A4'><select id='3E8AF7A8A4'><dt id='3E8AF7A8A4'><span id='3E8AF7A8A4'></span></dt></select></label></b><u id='3E8AF7A8A4'></u>
          <i id='3E8AF7A8A4'><strike id='3E8AF7A8A4'><tt id='3E8AF7A8A4'><pre id='3E8AF7A8A4'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-10-02 09:30:00 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：585
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Readout Newsletter: Novo Nordisk trial, Verve base editing, etc
                                
                            
          Next article：  
                                      
                                          Novavax promises a turnaround & Lilly roils the obesity market
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles